Harrison Kordestani
Vorstandsvorsitzender bei RICH PHARMACEUTICALS, INC.
Profil
Harrison Kordestani is currently the Chief Executive Officer & Director at Rich Pharmaceuticals, Inc. and also holds a position as Manager-Finance, Acquisitions & Production at Arclight Films Pty Ltd.
Previously, he worked as a Compliance Officer at Geopulse Exploration, Inc.
Aktive Positionen von Harrison Kordestani
| Unternehmen | Position | Beginn |
|---|---|---|
| RICH PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 29.06.2021 |
Arclight Films Pty Ltd.
 Arclight Films Pty Ltd. Movies/EntertainmentConsumer Services Arclight Films produces and distributes motion pictures. It focuses on international film sales and distribution services. The company has offices in Los Angeles, New York, London, Sydney, Melbourne, Toronto, and Hong Kong. The firm was founded by Victor Syrmis and Gary Hamilton in 2002 and is located in North Sydney, Australia. | Finanzdirektor/CFO | - |
Ehemalige bekannte Positionen von Harrison Kordestani
| Unternehmen | Position | Ende |
|---|---|---|
| GEOPULSE EXPLORATION, INC. | Compliance Officer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GEOPULSE EXPLORATION, INC. | Commercial Services |
| Private Unternehmen | 2 |
|---|---|
Arclight Films Pty Ltd.
Arclight Films Pty Ltd. Movies/EntertainmentConsumer Services Arclight Films produces and distributes motion pictures. It focuses on international film sales and distribution services. The company has offices in Los Angeles, New York, London, Sydney, Melbourne, Toronto, and Hong Kong. The firm was founded by Victor Syrmis and Gary Hamilton in 2002 and is located in North Sydney, Australia. | Consumer Services |
Rich Pharmaceuticals, Inc.
 Rich Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rich Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages on developing innovative therapies in oncology. It develops RP-323 for the treatment of Hodgkin’s lymphoma, Acute Myelogenous Leukemia, and to cause elevation of white blood cells in patients depleted of these elements due to various conditions. The company was founded on August 9, 2010 and is headquartered in Beverly Hills, CA. | Health Technology |
